TAIPEI, TAIWAN--(Marketwired - Mar 30, 2016) - BioBusiness Asia 2015 (BBA) kicked off a series of events and seminars that offered a perspective in Precision Medicine, Bio-ICT, IP strategies and explored global market trends, strategies with big pharma, and open innovation models. Held at CTBC Financial Hall in Nangang, Taipei, BBA provided a networking ground for Taiwan biopharma industry leaders, global researchers and influential pharma speakers. Session III titled Open Innovation and Partnering with Pharma, July 23rd, discussed the value of partnership and how it differs within the emerging markets such as Taiwan, China, Thailand, and Malaysia with speakers from AstraZeneca, Takeda Pharmaceuticals, Merck Research Laboratories, and Johnson and Johnson Innovation, Asia-Pacific. To highlight recent National Research Program for Biopharmaceuticals (NRPB, Taiwan) efforts on open innovation partnership particularly between academic and industry, Asia and Emerging Market's Executive Director & Head of Collaborations at AstraZeneca and New Frontier Science Director from Takeda Pharmaceuticals presented successful business models and approaches to collaboration with NRPB. A case study on collaboration model between AstraZeneca and NRPB focusing on drug repositioning project highlighted critical elements and obstacles encountered to push forward this pioneer project in Taiwan.

More than 200 registered for the event, where business executives and community leaders gathered at the CTBC Financial Hall to hear examples of open innovation successes and forecasts about future health care and collaboration models.

About Development Center for Biotechnology, Taiwan
DCB is a not-for-profit research organization, founded in 1984 and supported by government funding and private donations. DCB's objective is to advance Taiwan's biotech-pharma industry by building infrastructure, developing key technologies, and training talented workforces in coordination with government, industry, and academic institutions. DCB positions itself as a "Preclinical Value-Adding R&D Center for Biopharmaceuticals". This role is to be fulfilled by devoting concerted R&D efforts on protein, small molecule and botanical drug leads in the preclinical stage of development and setting top priorities for attaining Investigational New Drug approvals by domestic and foreign regulatory agencies. Please see website for more details at

Contact Information:

Press contact:
Daisy Tsai